FDA nod to first treatment for neurological symptoms of Type 3 Gaucher disease
By: IPP Bureau
Last updated : November 22, 2026 8:40 am
The drug is designed to cross the blood-brain barrier
The US FDA has approved Infilbray (venglustat) tablets, marking a major breakthrough in the treatment of Type 3 Gaucher disease (GD3).
It is the first treatment specifically approved for the neurological symptoms of the rare inherited disorder in adults and pediatric patients weighing at least 15 kg.
The drug is designed to cross the blood-brain barrier, targeting the accumulation of harmful substances in the brain — a key driver of the neurological complications associated with GD3.
“For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms,” said Acting FDA Commissioner Kyle Diamantas.
“This approval reflects the FDA’s commitment to advancing therapeutic options for patients with rare diseases and brings an important new treatment to patients and the healthcare providers who care for them.”
Type 3 Gaucher disease is a rare genetic disorder caused by a deficient or malfunctioning enzyme that prevents the body from properly breaking down fatty substances known as glucosphingolipids. Their accumulation in organs, tissues and the brain can trigger serious health complications over time.
Unlike Type 1 Gaucher disease, GD3 affects the central nervous system, causing neurological problems such as impaired balance, poor coordination, speech difficulties, memory loss and cognitive impairment. These symptoms can progressively worsen, significantly affecting patients' daily lives and quality of life.
Infilbray belongs to a class of drugs known as glucosylceramide synthase inhibitors. It works by reducing the production and buildup of harmful substances throughout the body, including the brain.
The FDA's decision was based on a randomized, double-blind, multicenter clinical trial involving 43 patients aged 12 years and older with GD3. All participants had previously received enzyme replacement therapy and achieved stabilization of their systemic disease.
Patients were assigned to receive either once-daily oral Infilbray or intravenous enzyme replacement therapy every two weeks for 52 weeks.
Researchers assessed treatment effectiveness using two measures focused on neurological function, including ataxia — the loss of muscle control and coordination — and cognitive performance.
At Week 52, patients receiving Infilbray showed improvement on a combined measure of the two neurological assessments compared with patients receiving enzyme replacement therapy for the non-neurological manifestations of GD3.
Despite the potential benefits, the drug carries important safety warnings.
The most commonly reported side effects include gastrointestinal symptoms and mood-related adverse effects. Serious psychiatric risks, including suicidal thoughts and behaviour, have also been reported.
Animal studies identified additional potential risks, including clouding of vision in younger patients and harmful effects on fetal development when the drug is taken during pregnancy.
The FDA has advised healthcare providers and patients to consult the drug's prescribing information for a full account of its safety profile and potential side effects.
Infilbray received Orphan Drug designation and Priority Review from the FDA, reflecting the regulatory focus on treatments for serious rare diseases with limited therapeutic options.
The approval was granted to Genzyme Corporation, a Sanofi company.
The decision introduces a new treatment approach for GD3, addressing neurological complications that have posed a significant challenge in managing the disease.